AJP - GI Journal of Neurophysiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol (September 15, 2005). doi:10.1152/ajpgi.00242.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/1/G129    most recent
00242.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishimura, N.
Right arrow Articles by Gores, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishimura, N.
Right arrow Articles by Gores, G. J.
Submitted on May 25, 2005
Accepted on August 23, 2005

TRAIL Induces Cell Migration and Invasion in Apoptosis-Resistant Cholangiocarcinoma Cells

Norihisa Ishimura1, Hajime Isomoto1, Steven F. Bronk1, and Gregory J. Gores1*

1 Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

* To whom correspondence should be addressed. E-mail: gores.gregory{at}mayo.edu.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent for cancer therapy; however, many cholangiocarcinoma cells are resistant to TRAIL-mediated apoptosis. Resistance to apoptosis may unmask TRAIL signaling cascades favoring tumor biology. Thus, our aim was to examine whether TRAIL is expressed by human cholangiocarcinomas, and if so, does it promote a malignant phenotype. To address this objective, TRAIL expression in human liver specimens was evaluated by immunohistochemistry. The effect of TRAIL on tumor cell migration, invasion, and proliferation was examined in three human cholangiocarcinoma cell lines. TRAIL expression was up-regulated by cholangiocytes in the preneoplastic disease, primary sclerosing cholangitis, and in human cholangiocarcinoma specimens. TRAIL promoted tumor cell migration and invasion, but did not induce cell proliferation. TRAIL-mediated cell migration and invasion was nuclear factor-{kappa}B (NF-{kappa}B) dependent. These data demonstrate that TRAIL promotes cell migration and invasion via a NF-{kappa}B-dependent pathway in human cholangiocarcinoma cell lines; an observation which has a potential negative implication for TRAIL in cancer therapy.




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. E. Guicciardi and G. J. Gores
Life and death by death receptors
FASEB J, June 1, 2009; 23(6): 1625 - 1637.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Takeda, Y. Kojima, K. Ikejima, K. Harada, S. Yamashina, K. Okumura, T. Aoyama, S. Frese, H. Ikeda, N. M. Haynes, et al.
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
PNAS, August 5, 2008; 105(31): 10895 - 10900.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Mott, S. F. Bronk, R. A. Mesa, S. H. Kaufmann, and G. J. Gores
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
Mol. Cancer Ther., August 1, 2008; 7(8): 2339 - 2347.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. S. Prabhakar, N. Mulherkar, and K. V. Prasad
Role of IG20 Splice Variants in TRAIL Resistance
Clin. Cancer Res., January 15, 2008; 14(2): 347 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. van Geelen, J. L. Westra, E. G. de Vries, W. Boersma-van Ek, N. Zwart, H. Hollema, H. M. Boezen, N. H. Mulder, J. T. Plukker, S. de Jong, et al.
Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
J. Clin. Oncol., November 1, 2006; 24(31): 4998 - 5004.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.